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Table 1
Cytokines as predictors of progression of outcomes of osteoarthritis. Odds ratios (OR) with 95% conﬁdence intervals (CI) from logistic regression analysis with adjustments for
sex, age and body mass index at ﬁrst examination, and time between examinations. Statistically signiﬁcant associations are indicated in bold.
Synovial ﬂuid conc.
exam 1 (n ¼ 132)
Synovial ﬂuid conc.
exam 2 (n ¼ 71)
Delta conc.
(2e1) (n ¼ 71)
Increased conc.
(2 > 1) (n ¼ 71)
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Radiographic progression
Loss of joint space IL-6
IL-8
TNF-a
1.02 (0.99, 1.06)
1.04 (0.99, 1.09)
1.01 (0.80, 1.28)
1.00 (1.00, 1.01)
1.00 (1.00, 1.01)
1.70 (1.15, 2.52)
1.00 (1.00, 1.01)
1.00 (0.99, 1.01)
1.34 (1.06, 1.71)
5.17 (1.54, 17.32)
2.37 (0.65, 8.61)
5.01 (1.32, 18.92)
Osteophyte progression IL-6
IL-8
TNF-a
1.05 (1.00, 1.09)
1.05 (0.99, 1.10)
1.35 (1.03, 1.75)
1.00 (1.00, 1.01)
1.00 (0.99, 1.01)
1.05 (0.82, 1.36)
1.00 (0.99, 1.01)
1.00 (0.99, 1.01)
0.90 (0.73, 1.11)
1.51 (0.49, 4.66)
1.33 (0.37, 4.79)
0.71 (0.22, 2.35)
ROA progression IL-6
IL-8
TNF-a
1.05 (0.98, 1.13)
1.03 (0.97, 1.10)
1.24 (0.90, 1.70)
1.00 (0.99, 1.01)
1.00 (0.99, 1.01)
1.27 (0.91, 1.76)
1.00 (0.99, 1.01)
1.00 (0.99, 1.01)
1.07 (0.84, 1.37)
2.70 (0.80, 9.13)
2.73 (0.67, 11.03)
1.41 (0.36, 5.55)
KOOS progression
Pain IL-6
IL-8
TNF-a
1.01 (0.99, 1.03)
1.02 (0.97, 1.08)
1.12 (0.87, 1.44)
1.00 (0.99, 1.01)
1.00 (0.99, 1.01)
1.16 (0.88, 1.54)
1.00 (0.99, 1.01)
1.00 (0.99, 1.01)
1.11 (0.88, 1.38)
1.02 (0.29, 3.52)
1.29 (0.30, 5.64)
1.72 (0.40, 7.34)
Other symptoms IL-6
IL-8
TNF-a
1.00 (0.98, 1.02)
1.00 (0.95, 1.06)
1.08 (0.84, 1.40)
1.00 (0.99, 1.01)
1.00 (0.99, 1.01)
0.97 (0.72, 1.31)
1.00 (0.99, 1.01)
1.00 (0.99, 1.01)
0.99 (0.79, 1.24)
1.71 (0.46, 6.37)
1.63 (0.37, 7.16)
1.27 (0.32, 5.04)
Function of daily living IL-6
IL-8
TNF-a
1.01 (1.00, 1.03)
1.04 (0.99, 1.10)
1.18 (0.90, 1,55)
1.01 (1.00, 1.01)
1.00 (0.99, 1.01)
1.50 (1.07, 2.09)
1.01 (1.00, 1.01)
1.00 (0.99, 1.01)
1.25 (0.97, 1.62)
0.97 (0.24, 3.89)
0.99 (0.21, 4.57)
7.25 (0.81, 65.33)
Function in sports
and recreation
IL-6
IL-8
TNF-a
1.08 (1.01, 1.14)
1.04 (0.98, 1.09)
1.06 (0.83, 1.36)
1.00 (0.99, 1.01)
1.00 (0.99, 1.01)
1.17 (0.89, 1.53)
1.00 (0.99, 1.01)
1.00 (0.99, 1.01)
1.09 (0.88, 1.34)
1.29 (0.38, 4.32)
1.24 (0.33, 4.67)
1.65 (0.45, 6.09)
Knee-related quality of life IL-6
IL-8
TNF-a
1.02 (0.99, 1.04)
1.03 (0.98, 1.08)
1.16 (0.90, 1.48)
1.00 (1.00, 1.01)
1.00 (0.99, 1.01)
0.81 (0.58, 1.11)
1.00 (0.99, 1.01)
1.00 (0.99, 1.01)
0.83 (0.65, 1.06)
0.73 (0.21, 2.57)
0.67 (0.18, 2.53)
0.86 (0.23, 3.19)
Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81 A51atlas with loss of joint space and osteophyte progression evaluated
separately as well as combined (to a radiographic score). Progression
from ﬁrst to second examination was deﬁned by increase of one or
more in grade or score. We evaluated patient-reported outcomes by
separate analysis of the ﬁve subscales of the Knee injury and Osteo-
arthritis Outcome Score (KOOS; Table 1), with progression deﬁned as a
worsening in the subscale score by 10 units or more. To study asso-
ciations between cytokine concentrations and progression of out-
comes, we used multivariate logistic regression analysis. The odds
ratios (OR) reﬂect higher concentration, or change in concentration
between visits, in increments of 1 pg/ml, or having increased in con-
centration or not. We did not use multiple test adjustments due to the
exploratory character of the study.
Results: At group level, synovial ﬂuid concentrations of IL-6, IL-8 and
TNF-a all increased between examinations (Fig. 1B). At the ﬁrst
examination, there was an overall trend for increased likelihood of
progression of radiographic features of OA in the subsequent years
with higher synovial ﬂuid cytokine levels (mean OR 1.1; Table 1). This
was most pronounced for osteophytes, for which higher concen-
trations of IL-6 (OR 1.05) and TNF-a (OR 1.35) were associated with
progression (Table 1). For patient-relevant outcomes, the only asso-
ciation found was between IL-6 and worsening of the KOOS domain
Sports and Recreation (OR 1.08; Table 1). At the second examination,
higher concentrations of TNF-a (but not IL-6 and IL-8) was associated
with having progressed in loss of joint space (OR 1.70) or worsened
in function of daily living (OR 1.50) in the preceding years (Table 1).
We further found that for the change in cytokine concentrations
between examinations, increase in TNF-a (but not in IL-6 or IL-8) was
associated with progression of loss of joint space (OR 1.34; Table 1).
With change in cytokine concentrations dichotomized as ‘increasing
vs. not increasing’, we found that those who had increased in con-
centrations of IL-6 or TNF-a from ﬁrst to second examination had a
5-fold increased likelihood of having progressed in loss of joint space
as compared to those with stable or decreasing concentrations
(Table 1).
Conclusions: In middle-aged subjects with previous meniscectomy,
having high or over time increasing synovial ﬂuid levels of IL-6 and TNF-
a was associated with increased risk for progression of radiographic
features of OA over four to ten years. Although our results need con-
ﬁrmation in prospective studies, they indicate that IL-6 or TNF-a may
represent valid treatment targets in knee OA.46
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Purpose: We and others have demonstrated low grade inﬂammation
exists in OA joint tissues, where it may contribute to disease patho-
genesis. In the current studies we assessed whether inﬂammatory
events occurring within joint tissues were reported in the peripheral
blood leukocytes (PBLs) of patients with symptomatic knee OA (SKOA).
Methods: PBL inﬂammatory gene expression (IL-1, TNFa, COX-2) was
assessed in two independent cohorts of patients with SKOA, and a
cohort of healthy control subjects: 1) 111 patients with tibiofemoral
medial OA and 21 healthy volunteers from the NYUHJD Cohort, and 2)
200 patients from the OAI progression cohort who had “high quality
radiographs”, at both baseline and 24 months, and had KL2 or 3 in the
signal knee at baseline. Radiographic progression was deﬁned as nar-
rowing of medial joint space width (JSW) in the signal knee between
baseline and 24-months in each cohort. Radiographic progressors were
deﬁned as subjects who had JSN >0.0, 0.2 and 0.5mm over 24 months.
For measuring predictive performance, we used the area under the
curve (AUC) of a receiver operating characteristics (ROC). OAI SKOA
subjects were dichotomized as radiographic non-progressors (JSN <0.0
mm) and progressors (JSN>0.0mm) for association studies.
Results: Elevated PBL expression of IL-1, TNFa or COX-2 identiﬁed SKOA
patients who were “fast progressors” (mean JSN 0¼ 0.71, 0.75 and 0.71
mm / 24 months, respectively) compared to patients with levels below
the median. In a multivariable model, anthropometric traits alone (BMI,
gender, age) did not predict progression, whereas addition of PBL gene
expressions improved prediction of fast progressors (JSN>0.5mm). We
next examined inﬂammatory gene expression in PBLs of radiographic
Table 1
Area under the curve (AUC) of a receiver operating characteristics (ROC) of PBL
inﬂammatory gene expression for distinguishing radiographic progressors from
non-progressors in the OAI cohort. For multivariable models, we used 10-fold
stratiﬁed cross-validation repeated with 100 different splits of data into different
splits of data into 10-folds.
Progressors (JSN>0.0mm)
vs.non-Progressors
(JSN<0.0mm)
AUC CI P value
IL-1b 0.750 0.66e0.84 0.0000
TNFa 0.674 0.58e0.77 0.0002
COX-2 0.621 0.52e0.72 0.0095
IL-1b þ TNFa þ COX-2 0.611 0.51e0.71 0.0170
Progressors (JSN>0.2mm)
vs non-Progressors
(JSN<0.0mm)
AUC CI P value
IL-1b 0.755 0.06 - 0.65 0.0000
TNFa 0.674 0.57 - 0.73 0.0002
COX-2 0.614 0.50 - 0.72 0.0204
IL-1b þ TNFa þ COX-2 0.719 0.62 e 0.82 0.0000
Progressors (JSN>0.5mm)
vs non-Progressors
(JSN<0.0mm)
AUC CI P value
IL-1b 0.758 0.65e0.87 0.0000
TNFa 0.675 0.56e0.79 0.0015
COX-2 0 611 0.49e0.73 0.0382
IL-1b þ TNFa þ COX-2 0.730 0.62e0.84 0.0000
Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81A52progressors in the OAI cohort. Similar to the NYUHJD cohort, elevated
expression of IL-1b, TNFa and COX-2 mRNA distinguished radiographic
progressors from non-progressors (Table 1). PBL IL-1b expression found
to be strongest predictor of all three radiographic progressors. In mul-
tivariate models that combine all three markers did not improve upon
IL-1b predictivity. We thus conclude that either the signal in TNFa and
Cox-2 is already subsumed by IL-1b and/or that it is not easy to capture
the non-overlapping signals without increasing the sample size (i.e.,
ﬁtting a stronger multivariate predictor will require more sample size).
Conclusions: We identiﬁed, and conﬁrmed in two cohorts, increased
inﬂammatory gene expression (IL-1, TNFa or COX-2) by PBLs that pre-
dict radiographic progression in patients with SKOA. The data indicate
that inﬂammatory events within joint tissues of patients with SKOA are
reported in the peripheral blood. These PBL transcriptome signals of
local joint inﬂammation merit further study as potential biomarkers for
OA disease progression.
47
CHANGES IN ARGS-AGGRECAN, C-TERMINAL TYPE II AND N-
TERMINAL TYPE I COLLAGEN TELOPEPTIDES, AND CYTOKINE
CONCENTRATIONS OVER FIVE YEARS AFTER ANTERIOR CRUCIATE
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Correlation analysis between biomarkers. Spearman’s rank order correlation (p-values) b
avoid repeated observations, each subject contributed samples at one time point only. S
Synovial ﬂuid ARGS Serum
Synovial ﬂuid IL-6 0.479 (<0.001) 0.130
Synovial ﬂuid IL-8 0.409 (<0.001) 0.089
Synovial ﬂuid IL-10 0.492 (<0.001) 0.073
Synovial ﬂuid IFN-g 0.460 (<0.001) 0.257
Synovial ﬂuid NF-a 0.438 (<0.001) 0.075
Synovial ﬂuid ARGS e 0.359
Serum ARGS e
Urine CTX-II
Urine NTX-IPurpose: Rupture of the anterior cruciate ligament (ACL) leads to an
increased risk of developing knee osteoarthritis (OA). Mechanisms
behind this development are not fully understood, and analysis of
biomarkers could be used for elucidating these biological processes but
also to detect and predict joint pathology and post traumatic OA. We
prospectively monitored levels of synovial ﬂuid and serum pro-
inﬂammatory cytokines and aggrecan ARGS neoepitope, and urine C-
terminal type II (CTX-II) and N-terminal type I (NTX-I) collagen telo-
peptides over ﬁve years after ACL rupture.
Methods: Synovialﬂuid, serumandurinewere collected from121 adults
at baseline (0-6weeks after injury),16, 30and52weeks, and twoandﬁve
years after an acute ACL injury (the KANON trial, ISRCTN 84752559,
http://www.controlled-trials.com). Reference samples: synovial ﬂuid (n
¼ 21), serum (n ¼ 23) and urine (n ¼ 62) were from knee healthy vol-
unteers. Synovialﬂuid and serumconcentrations of interleukin (IL)-6, IL-
8, IL-10, interferon (IFN)-g, and tumor necrosis factor (TNF)-a were
measured by a multiplex immunoassay from Meso Scale Discovery
(MSD), and ARGS-aggrecan was analyzed by an in-house immunoassay
assay. Urine levels of CTX-II and NTX-I were measured by ELISA assays
from IDS and Osteomark, and were corrected for urine creatinine levels
(CREP2, Roche). Concentrations of cytokines, ARGS-aggrecan and colla-
gen telopeptides were not normally distributed. We used Mann-Whit-
ney tests for group comparisons and Spearman’s rank test (rS) for
correlation analysis. To estimate time until the synovial ﬂuid biomarker
concentrations had decreased to half that of the value at baseline
(‘concentration half-life’) amixedvariance componentsmodelwas used.
Results: At baseline (0-6 weeks after injury), synovial ﬂuid cytokine
concentrations were elevated 6- (TNF-a, p < 0.001), 7- (IL-8, p < 0.001),
13- (IFN-g, p < 0.001), 21- (IL-10, p < 0.001) and 1050-fold (IL-6, p <
0.001) compared to knee healthy reference levels. This increase was not
observed in serum cytokine concentrations. Synovial ﬂuid and serum
ARGS-aggrecan, and urine CTX-II concentrations were elevated 8- (p <
0.001), 1.4- (p ¼ 0.002) and 1.5-fold (p ¼ 0.009) respectively, while
baseline urine NTX-I levels were no different from the reference. At time
periods after baseline, concentrations of synovial ﬂuid cytokines and
ARGS-aggrecan, and urine CTX-II and NTX-I decreased rapidly, where
ARGS-aggrecan and cytokines showed the following statistically sig-
niﬁcant mean concentration half-lives, in years: IL-6 0.9, IL-8 2.2, IL-10
2.3, IFN-g 3.1, TNF-a 3.6, ARGS-aggrecan 4.0. Five years after injury, the
synovial ﬂuid TNF-a concentration was still higher (1.7-fold, p ¼ 0.044)
than the reference level, the urine NTX-I level was lower (0.5-fold, p <
0.001), while the concentration of the other markers were at the same
level as seen in references. Over the ﬁve year period, there was a cor-
relation between synovial ﬂuid and serum ARGS-aggrecan concen-
trations (rS ¼ 0.36, p < 0.001), and between serum and synovial ﬂuid
ARGS-aggrecan and urine CTX-II levels (rS ¼ 0.36, p < 0.001 and rS ¼
0.26, p ¼ 0.006, respectively) (Table 1). Synovial ﬂuid cytokine con-
centrations correlated with synovial ﬂuid ARGS-aggrecan level (rS ¼
0.41 to 0.49, p < 0.001) and with levels of urine collagen telopeptides (rS
¼ 0.21 to 0.31, p ¼ 0.001 to 0.028) (Table 1).
Conclusions: Acute ACL injury induced high levels of proinﬂammatory
cytokines in the joint which were associated with proteolysis of
aggrecan and type II collagen. This trauma induced joint inﬂammation
persisted many years after ACL injury, and together with the reduction
of bone turnover, seen several years after injury as decreased urine NTX-
I levels, may eventually result in permanent cartilage damage and the
development of post traumatic OA.etween biomarkers in different body ﬂuids from ACL injured subjects (n ¼ 121). To
tatistically signiﬁcant correlations are in bold. ARGS, ARGS neoepitope of aggrecan.
ARGS Urine CTX-II Urine NTX-I
(0.173) 0.263 (0.006) 0.211 (0.028)
(0.353) 0.276 (0.004) 0.181 (0.059)
(0.443) 0.264 (0.006) 0.146 (0.129)
(0.006) 0.309 (0.001) 0.278 (0.003)
(0.434) 0.297 (0.002) 0.232 (0.015)
(<0.001) 0.258 (0.006) 0.112 (0.243)
0.356 (<0.001) 0.086 (0.353)
- 0.691 (<0.001)
e
